The abstract is read at the publisher; the summary is JClub's.
ABC-301, a recombinant human sIgA1 with Adalimumab binding regions, neutralizes human TNF in vitro with a whole-molecule molar IC50 about 3.3-fold lower than Adalimumab.
- Why it matters: IgG reformatting into secretory IgA could enable mucosal delivery, but preclinical evidence is needed for function, oral efficacy, biodistribution, and resistance to anti-Adalimumab antibodies.
- What they did: The study tested human TNF binding and functional neutralization in vitro, compared molar neutralization IC50 values (including binding-site normalization), dosed orally in DSS-induced colitis, tracked iodine-125 biodistribution, and assessed susceptibility across seven patient-derived anti-Adalimumab preparations.
- The result: In DSS-induced colitis, oral ABC-301 attenuated colon shortening and reduced colonic inflammatory myeloid populations and tissue inflammatory biomarkers versus untreated DSS controls, with radioactivity mainly in gastrointestinal compartments and reduced functional inhibition by patient antibodies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.